Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
20
07
2020
accepted:
05
12
2020
pubmed:
13
1
2021
medline:
10
9
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
To analyze safety and efficacy of the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system in patients with type 1 diabetes in real-world conditions. After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA The mean (SD; range) age of patients was 43 (13.8; 25-72) years. At baseline, the mean HbA The ability of the DBLG1 system to significantly improve glycemic control in real-world conditions, without serious adverse events, was confirmed in this follow-up study.
Identifiants
pubmed: 33431420
pii: dc20-1809
doi: 10.2337/dc20-1809
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Banques de données
figshare
['10.2337/figshare.13583129']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
844-846Informations de copyright
© 2021 by the American Diabetes Association.